A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS
- Conditions
- Mycobacterium Avium-Intracellulare InfectionHIV Infections
- Registration Number
- NCT00001995
- Lead Sponsor
- Pharmacia
- Brief Summary
To determine if a drug regimen containing rifabutin will eradicate or decrease the numbers of Mycobacterium avium complex (MAC) organisms in blood, improve the symptoms associated with MAC infection, and increase survival in patients with AIDS. To assess the safety of the drug regimen.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (21)
Maricopa County Med Ctr
🇺🇸Phoenix, Arizona, United States
Bay Harbor Hosp
🇺🇸Harbor City, California, United States
Ctr for Special Immunology
🇺🇸Fort Lauderdale, Florida, United States
Southwest Community Based AIDS Treatment Group - COMBAT
🇺🇸Los Angeles, California, United States
AIDS Community Research Consortium
🇺🇸Redwood City, California, United States
HIV Research Group
🇺🇸San Diego, California, United States
Davies Med Ctr
🇺🇸San Francisco, California, United States
San Francisco Veterans Administration Med Ctr
🇺🇸San Francisco, California, United States
Veterans Administration Med Ctr
🇺🇸Washington, District of Columbia, United States
TheraFirst Med Ctrs Inc
🇺🇸Fort Lauderdale, Florida, United States
Scroll for more (11 remaining)Maricopa County Med Ctr🇺🇸Phoenix, Arizona, United States